Resolution to issue new shares for capital
increase through profits by Board of Directors
Date of events
2022/03/01
To which item it meets
paragraph 11
Statement
1.Date of the board of directors resolution:2022/03/01
2.Source of capital increase funds:2021 profits
3.Whether to adopt shelf registration
(Yes, please state issuance period/No):No
4.Total monetary value of the issuance and number of shares issued (shares
issued not including those distributed to employees if consisting in
capital increase from earnings or capital surplus):
Total monetary value of the issuance:NTD 1,067,195,500
Number of shares issued:106,719,550 shares
5.If adopting shelf registration, monetary value and number of shares
to be issued this time:N/A
6.The remaining monetary value and shares after this issuance when
adopting shelf registration:N/A
7.Par value per share:NTD 10
8.Issue price:N/A
9.Number of shares subscribed for by or allocated to employees:N/A
10.Number of shares publicly sold:N/A
11.Ratio of shares subscribed by or allotted as stock
dividends to existing shareholders:
Receive 500 shares for each 1,000 shares.
12.Handling method for fractional shares and shares
unsubscripted for by the deadline:
If there are less than 1 share of abnormal shares allotted, the shareholders
shall make up their own shares within 5 days from the date of closing the
transfer of accounts. If there is still less than 1 share after making up or
the share has not been made up within the time limit, the denomination will
be converted into cash and calculated up to NTD (all below NTD are rounded
up),Then authorize the chairman to negotiate with a specific person to
purchase at face value.
13.Rights and obligations of these newly issued shares:
The rights and obligations of this capital increase are the
same as those of the existing issued common shares.
14.Utilization of the funds from the capital increase:
Enrichment of working capital
15.Any other matters that need to be specified:
(1)The rights and obligations of insubstantial shares in this capital
increase are the same as those of the original shares. After being
approved by the regular shareholders' meeting and submitted to the
competent authority for approval, the board of directors is authorized
to determine the ex-rights allotment base date, distribution date and
other related matters.
(2)If the company subsequently repurchases the company's shares to carry
out the transfer or cancellation of treasury shares, or the conversion
of domestic convertible corporate bonds, which affects the number of
shares in circulation and the shareholders' allotment rate changes as
a result, it is proposed to request the shareholders' meeting to
authorize the chairman of the board.Handle changes related matters.
(3)If the above-mentioned matters related to capital increase and issuance
of new shares need to be amended due to the regulations of the competent
authority or the objective environmental impact, it is proposed to submit
to the shareholders' meeting to authorize the chairman to handle them
with full authority.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Medigen Vaccine Biologics Corporation published this content on 01 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 March 2022 08:27:03 UTC.
Medigen Vaccine Biologics Corp is a Taiwan-based company principally engaged in the development and manufacture of vaccines and biological agents. The Company is engaged in the research, design, development, manufacture, and sale of cell culture vaccines such as influenza vaccines, enterovirus vaccines and dengue vaccines, as well as other biological agents. The main products include enterovirus 71 vaccines (Envacgen), quadrivalent seasonal influenza vaccines, and coronavirus disease 2019 (COVID-19) vaccines. The Company primarily distributes products in Taiwan.